Market Closed -
Other stock markets
|
After market 12:34:14 pm | |||
39.75 EUR | +0.91% | 39.76 | +0.03% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 05 | Dpa-AFX Overview: COMPANIES from 05.06.2024 - 15:15 | DP |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.72% | 12.58B | A- | ||
+23.97% | 88.22B | C+ | ||
-21.95% | 76.5B | B- | ||
+1.76% | 26.97B | C+ | ||
+7.94% | 18.61B | A- | ||
-12.78% | 16.72B | B | ||
+3.49% | 15.85B | A- | ||
+75.13% | 13.41B | C- | ||
+77.36% | 13.16B | C+ | ||
+23.31% | 12.67B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FME Stock
- Ratings Fresenius Medical Care AG